• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    12 Health Care Stocks Moving In Thursday's Intraday Session

    5/23/24 12:31:11 PM ET
    $CYTK
    $CYTO
    $DMTK
    $HLTH
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $CYTK alert in real time by email

    Gainers

    • OneMedNet (NASDAQ:ONMD) shares moved upwards by 118.4% to $1.07 during Thursday's regular session. The market value of their outstanding shares is at $25.5 million.
    • Renovaro (NASDAQ:RENB) stock rose 46.79% to $1.38. The company's market cap stands at $203.5 million.
    • Altamira Therapeutics (NASDAQ:CYTO) shares increased by 29.37% to $1.85. The company's market cap stands at $4.1 million.
    • Purple Biotech (NASDAQ:PPBT) stock rose 23.44% to $0.84. The company's market cap stands at $21.9 million. As per the press release, Q1 earnings came out 2 days ago.
    • P3 Health Partners (NASDAQ:PIII) stock increased by 23.04% to $0.62. The market value of their outstanding shares is at $73.8 million.
    • Qilian Intl Hldg Gr (NASDAQ:QLI) stock moved upwards by 22.39% to $0.71. The market value of their outstanding shares is at $25.3 million.

    Losers

    • SILO Pharma (NASDAQ:SILO) shares fell 17.8% to $1.89 during Thursday's regular session. The company's market cap stands at $5.2 million.
    • Cue Health (NASDAQ:HLTH) shares fell 16.92% to $0.09. The market value of their outstanding shares is at $14.1 million.
    • Protagenic Therapeutics (NASDAQ:PTIX) shares declined by 16.08% to $1.51. The company's market cap stands at $6.6 million.
    • Cytokinetics (NASDAQ:CYTK) shares decreased by 15.51% to $50.05. The market value of their outstanding shares is at $5.2 billion.
    • SAB Biotherapeutics (NASDAQ:SABS) shares fell 15.5% to $2.4. The market value of their outstanding shares is at $22.1 million. As per the news, the Q1 earnings report came out 3 days ago.
    • DermTech (NASDAQ:DMTK) stock declined by 14.05% to $0.36. The company's market cap stands at $12.6 million. See Also: www.benzinga.com/money/best-healthcare-stocks/

    This article was generated by Benzinga's automated content engine and reviewed by an editor.

    Get the next $CYTK alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $CYTK
    $CYTO
    $DMTK
    $HLTH

    CompanyDatePrice TargetRatingAnalyst
    Cytokinetics Incorporated
    $CYTK
    1/28/2026$87.00Overweight
    Barclays
    SAB Biotherapeutics Inc.
    $SABS
    12/19/2025$15.00Buy
    Guggenheim
    Cytokinetics Incorporated
    $CYTK
    12/18/2025$95.00Neutral → Buy
    Goldman
    SAB Biotherapeutics Inc.
    $SABS
    9/17/2025$7.00Outperform
    Leerink Partners
    P3 Health Partners Inc.
    $PIII
    8/28/2025$20.00Buy
    Lake Street
    Cytokinetics Incorporated
    $CYTK
    7/30/2025Mkt Perform
    Raymond James
    SAB Biotherapeutics Inc.
    $SABS
    5/14/2025$10.00Buy
    H.C. Wainwright
    Cytokinetics Incorporated
    $CYTK
    4/24/2025$55.00Overweight
    Barclays
    More analyst ratings

    $CYTK
    $CYTO
    $DMTK
    $HLTH
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Barclays resumed coverage on Cytokinetics with a new price target

    Barclays resumed coverage of Cytokinetics with a rating of Overweight and set a new price target of $87.00

    1/28/26 7:16:37 AM ET
    $CYTK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Guggenheim initiated coverage on SAB BIO with a new price target

    Guggenheim initiated coverage of SAB BIO with a rating of Buy and set a new price target of $15.00

    12/19/25 8:51:08 AM ET
    $SABS
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Cytokinetics upgraded by Goldman with a new price target

    Goldman upgraded Cytokinetics from Neutral to Buy and set a new price target of $95.00

    12/18/25 8:41:18 AM ET
    $CYTK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CYTK
    $CYTO
    $DMTK
    $HLTH
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Executive Officer Weisblum Eric bought $2,075 worth of shares (5,000 units at $0.41), increasing direct ownership by 2% to 216,932 units (SEC Form 4)

    4 - Silo Pharma, Inc. (0001514183) (Issuer)

    12/16/25 6:34:59 PM ET
    $SILO
    Apparel
    Consumer Discretionary

    Chief Medical Officer Yu Jeffrey converted options into 2,307,549 shares, bought $959,586 worth of shares (2,010,479 units at $0.48) and was granted 245,000 shares, increasing direct ownership by 165% to 7,326,223 units (SEC Form 4)

    4 - OneMedNet Corp (0001849380) (Issuer)

    11/26/25 9:56:08 PM ET
    $ONMD
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    Chief Medical Officer Yu Jeffrey bought $8,929 worth of shares (9,540 units at $0.94) and was granted 230,769 shares, increasing direct ownership by 10% to 2,763,195 units (SEC Form 4)

    4 - OneMedNet Corp (0001849380) (Issuer)

    11/26/25 9:55:32 PM ET
    $ONMD
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    $CYTK
    $CYTO
    $DMTK
    $HLTH
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Cytokinetics to Participate in March Investor Conferences

    SOUTH SAN FRANCISCO, Calif., March 02, 2026 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (NASDAQ:CYTK) today announced that members of the Company management team will participate in the following investor conferences in March: Leerink 2026 Global Healthcare Conference: Fireside chat on Monday, March 9, 2026 at 9:20 AM Eastern Time in Miami Beach, FL.Citizens 2026 Life Sciences Conference: Fireside chat on Tuesday, March 10, 2026 at 9:00 AM Eastern Time in Miami Beach, FL.2026 Jefferies Biotech on the Beach Summit: One-on-one meetings on Wednesday, March 11, 2026 in Miami Beach, FL.Barclays 28th Annual Global Healthcare Conference: Fireside chat on Wednesday, March 11, 2026 at 2:30 PM E

    3/2/26 4:00:00 PM ET
    $CYTK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SAB BIO to Participate in Upcoming Investor Conferences

    MIAMI, March 02, 2026 (GLOBE NEWSWIRE) -- SAB Biotherapeutics, Inc. (Nasdaq: SABS), a clinical-stage biopharmaceutical company developing a fully human anti-thymocyte immunoglobulin (hATG) for type 1 diabetes (T1D) and other autoimmune diseases, today announced that members of its management team will participate in the following investor conferences in March: Leerink Partners Global Healthcare ConferenceDate: March 9, 2026Time: 3:00 p.m. ETFormat: Fireside Chat Location: Miami Beach, FL Barclays 28th Annual Global Healthcare ConferenceDate: March 11, 2026Time: 8:30 a.m. ETFormat: Fireside Chat Location: Miami Beach, FL To access a live webcast of these events, as well as an archived re

    3/2/26 9:00:00 AM ET
    $SABS
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    OneMedNet Announces Next Phase of Commercial Launch with its Real-World Data (RWD) Platform powered by Palantir Foundry

    MINNEAPOLIS, Feb. 27, 2026 (GLOBE NEWSWIRE) -- OneMedNet Corporation (NASDAQ:ONMD) (the "OneMedNet," the "Company," "we," "us" or "our"), a leading provider of regulatory-grade, AI-ready Real-World Data (RWD), today announced the next phase of commercial launch with its RWD Platform powered by Palantir Foundry. Following the successful November 10, 2025, demonstration of live feeds, subscription access, and AI-driven search at major tradeshows, the Company is actively converting customer evaluations into commercial subscriptions. Early results highlight superior performance, speed and analytical depth, reinforcing OneMedNet's position for life sciences and healthcare organizations generati

    2/27/26 8:50:00 AM ET
    $ONMD
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    $CYTK
    $CYTO
    $DMTK
    $HLTH
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    June 6, 2023 - FDA Permits Marketing of First COVID-19 At-Home Test Using Traditional Premarket Review Process

    For Immediate Release: June 06, 2023 Today, the U.S. Food and Drug Administration granted marketing authorization for the Cue COVID-19 Molecular Test. The product is a molecular nucleic acid amplification test (NAAT) that is intended to detect genetic material from SARS-CoV-2 virus present in nasal swabs from adults with signs and symptoms of upper respiratory infection. This test is the first at-home over-the-c

    6/6/23 3:04:14 PM ET
    $HLTH
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    $CYTK
    $CYTO
    $DMTK
    $HLTH
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    EVP, Chief Commercial Officer Callos Andrew exercised 26,000 shares at a strike of $29.97 and sold $1,608,730 worth of shares (26,000 units at $61.87) (SEC Form 4)

    4 - CYTOKINETICS INC (0001061983) (Issuer)

    3/5/26 4:27:52 PM ET
    $CYTK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Parshall B Lynne sold $306,050 worth of shares (5,000 units at $61.21), decreasing direct ownership by 22% to 17,933 units (SEC Form 4)

    4 - CYTOKINETICS INC (0001061983) (Issuer)

    3/2/26 4:29:56 PM ET
    $CYTK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    EVP, Chief Commercial Officer Callos Andrew exercised 886 shares at a strike of $37.63 and sold $54,595 worth of shares (886 units at $61.62) (SEC Form 4)

    4 - CYTOKINETICS INC (0001061983) (Issuer)

    3/2/26 4:28:06 PM ET
    $CYTK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CYTK
    $CYTO
    $DMTK
    $HLTH
    SEC Filings

    View All

    Protagenic Therapeutics Inc. filed SEC Form 8-K: Leadership Update

    8-K - Protagenic Therapeutics, Inc.\new (0001022899) (Filer)

    3/2/26 9:27:00 PM ET
    $PTIX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form S-8 filed by Cytokinetics Incorporated

    S-8 - CYTOKINETICS INC (0001061983) (Filer)

    2/26/26 5:35:35 PM ET
    $CYTK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 10-K filed by Cytokinetics Incorporated

    10-K - CYTOKINETICS INC (0001061983) (Filer)

    2/26/26 4:01:01 PM ET
    $CYTK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CYTK
    $CYTO
    $DMTK
    $HLTH
    Leadership Updates

    Live Leadership Updates

    View All

    Cytokinetics and Olympic Gold Medalist Sydney McLaughlin-Levrone Team Up to Raise Awareness of the Whole-Person Impact of Hypertrophic Cardiomyopathy (HCM)

    "On Track with HCM" Features Practical Insights for Managing Everyday Life with the Disease, Inspired by the Experience with HCM of McLaughlin-Levrone's Father, Willie McLaughlin SOUTH SAN FRANCISCO, Calif., Jan. 27, 2026 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (NASDAQ:CYTK) today announced the launch of "On Track with HCM," demonstrating the company's long-standing commitment to the HCM community. The campaign features four-time Olympic gold medalist Sydney McLaughlin-Levrone, and her father, three-time all-American track star, Willie McLaughlin, who suffered from the non-obstructive form of hypertrophic cardiomyopathy (HCM) for more than two decades before receiving a heart trans

    1/27/26 8:00:00 AM ET
    $CYTK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SAB BIO Strengthens Board of Directors with Appointment of New Chair and New Director

    David Zaccardelli, Pharm.D. joins Board as Chair Rita Jain, M.D., joins Board as an Independent Director MIAMI, Jan. 07, 2026 (GLOBE NEWSWIRE) -- SAB Biotherapeutics, Inc. (NASDAQ:SABS), a clinical-stage biopharmaceutical company developing a fully human anti-thymocyte immunoglobulin (hATG) for type 1 diabetes (T1D) and other autoimmune diseases, today announced the appointment of David Zaccardelli, Pharm.D. to its Board of Directors as Chair of the Board and the appointment of Rita Jain, M.D., as an independent director, both effective immediately. "We are excited to welcome Dr. David Zaccardelli and Dr. Rita Jain to our Board of Directors. I, along with the rest of our Board, am confi

    1/7/26 8:00:00 AM ET
    $SABS
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Cytokinetics Names Jim Daly to Board of Directors

    SOUTH SAN FRANCISCO, Calif., Aug. 20, 2025 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (NASDAQ:CYTK) today announced the appointment of James M. Daly to its Board of Directors effective August 19, 2025. Mr. Daly brings over 30 years of global biopharmaceutical leadership experience with particular expertise in commercialization to the Company's Board of Directors. "Jim has longstanding expertise leading commercial launches of innovative therapies, coupled with extensive Board experience guiding later-stage, global biopharma companies," said Robert I. Blum, Cytokinetics' President and Chief Executive Officer. "We are pleased to welcome him to our Board and look forward to his contributi

    8/20/25 7:30:00 AM ET
    $CYTK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CYTK
    $CYTO
    $DMTK
    $HLTH
    Financials

    Live finance-specific insights

    View All

    Cytokinetics Reports Fourth Quarter 2025 Financial Results and Provides Business Update

    MYQORZO® Approved for Adults with Symptomatic Obstructive HCM in U.S., China and Europe; U.S. Launch Underway with First Prescriptions Dispensed within Days of Drug Availability Supplemental NDA for MAPLE-HCM Submitted to FDA in Q1 2026 Expect to Share Topline Results from ACACIA-HCM in Q2 2026 Company Provides 2026 Financial Guidance;~$1.2 Billion in Cash, Cash Equivalents and Investments as of December 31, 2025 SOUTH SAN FRANCISCO, Calif., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (NASDAQ:CYTK) reported a management update and financial results for the fourth quarter and full year of 2025. The company also provided full year 2026 financial guidance. "The fourth qu

    2/24/26 4:00:00 PM ET
    $CYTK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Cytokinetics to Announce Fourth Quarter Results on February 24, 2026

    SOUTH SAN FRANCISCO, Calif., Feb. 12, 2026 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (NASDAQ:CYTK) today announced that it is scheduled to report fourth quarter results on February 24, 2026 at 4:00 PM Eastern Time. Following the announcement, Cytokinetics' senior management will host a conference call at 4:30 PM Eastern Time to discuss financial results and provide business updates. The conference call will be simultaneously webcast and can be accessed from the Investors & Media section of Cytokinetics' website at www.cytokinetics.com or directly at the following link: Cytokinetics Q4 2025 Earnings Conference Call. An archived replay of the webcast will be available via Cytokinetics'

    2/12/26 4:00:00 PM ET
    $CYTK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Cytokinetics Announces FDA Approval of MYQORZO™ (aficamten) for the Treatment of Adults with Symptomatic Obstructive Hypertrophic Cardiomyopathy to Improve Functional Capacity and Symptoms

    MYQORZO, a Cardiac Myosin Inhibitor, Directly Addresses Underlying Hypercontractility Associated with Obstructive HCM FDA Approval Based on Results of SEQUOIA-HCM MYQORZO is Company's First FDA-Approved Medicine Company to Host Investor Conference Call Today at 4:30 PM Eastern Time SOUTH SAN FRANCISCO, Calif., Dec. 19, 2025 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (NASDAQ:CYTK) today announced that the U.S. Food and Drug Administration (FDA) has approved MYQORZO™ (aficamten), 5 mg, 10 mg, 15 mg, 20 mg tablets for the treatment of adults with symptomatic obstructive hypertrophic cardiomyopathy (oHCM) to improve functional capacity and symptoms. MYQORZO is an allosteric and rever

    12/19/25 4:00:00 PM ET
    $CYTK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CYTK
    $CYTO
    $DMTK
    $HLTH
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Purple Biotech Ltd.

    SC 13G/A - PURPLE BIOTECH LTD. (0001614744) (Subject)

    11/14/24 5:21:29 PM ET
    $PPBT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Protagenic Therapeutics Inc.

    SC 13G/A - Protagenic Therapeutics, Inc.\new (0001022899) (Subject)

    11/14/24 5:19:32 PM ET
    $PTIX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed by P3 Health Partners Inc.

    SC 13G - P3 Health Partners Inc. (0001832511) (Subject)

    11/14/24 4:33:46 PM ET
    $PIII
    Medical/Nursing Services
    Health Care